Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
23-valent pneumococcal polysaccharide vaccine in subjects ≥2 years
CTR20150214Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Apr 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of 23-valent pneumococcal polysaccharide vaccine in Pneumococcal pneumonia (PP), pneumococcal disease, sponsored by Sinovac Biotech Ltd.. Started Apr 2015; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
Pneumococcal pneumonia (PP)pneumococcal disease
Beyond the preview
Go deeper on CTR20150214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150214.